Clinical trials in Trento – page 5

57 clinical trials in Trento, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Trento at a glance

clinical trials

Paediatric trials0
Research sites1

Quick filters

57 trials in Trento

Open in trial search

Prostate cancer metastatic

Not recruiting

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Pfizer Inc.

Contact Research Centre

Endometrial cancer stage III+1

Not recruiting

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Tesaro Inc.

Contact Research Centre

Breast cancer

Not recruiting

Study on Anastrozole, Letrozole, Exemestane, and Tamoxifen for Women Aged 70+ with Early Stage Breast Cancer

Registered drugNo placebo

Study on Anastrozole, Letrozole, Exemestane, and Tamoxifen for Women Aged 70+ with Early Stage Breast Cancer

Registered drugNo placebo

Italy

Participants:65+ years
Substances:Anastrozole
Sponsor:University Of Florence

Contact Research Centre

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

InvestigationalNo placebo

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Infertility female+1

Not recruiting

Study on Ovarian Response in Women with Infertility Using Follitropin Delta and Menotrophin During Assisted Reproductive Technology

Registered drugNo placebo

Study on Ovarian Response in Women with Infertility Using Follitropin Delta and Menotrophin During Assisted Reproductive Technology

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Follitropin Delta
Sponsor:Ferring Pharmaceuticals A/S

Contact Research Centre

Breast cancer+2

Not recruiting

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drugNo placebo

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Alpelisib
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Prostate cancer recurrent

Not recruiting

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Darolutamide
Sponsor:Bayer AG

Contact Research Centre

Orthostatic hypotension

Not recruiting

Study on Ampreloxetine and Midodrine Hydrochloride for Treating Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

Registered drug

Study on Ampreloxetine and Midodrine Hydrochloride for Treating Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Ampreloxetine
Sponsor:Theravance Biopharma Ireland Limited

Contact Research Centre

Hormone-refractory prostate cancer+1

Not recruiting

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Pfizer Inc.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Trento

What the registry says about research in the country

01 Oncology - Prostate Cancer

Innovative clinical trials focusing on metastatic castration-resistant prostate cancer, evaluating new therapeutic combinations and treatment sequences.

Novel hormone therapies
Targeted drug combinations
Radiation therapy approaches

Studies are examining both early-stage and advanced disease management strategies.

02 Oncology - Breast Cancer

Research initiatives exploring treatments for HER2-positive and HER2-low breast cancer, including studies for both early-stage and metastatic disease.

Targeted therapies
Hormone receptor studies
Novel drug combinations

Particular focus on personalized treatment approaches for different breast cancer subtypes.

03 Oncology - Other Cancers

Comprehensive studies investigating treatments for lung cancer, melanoma, and urothelial cancer.

Immunotherapy approaches
Maintenance therapies
Targeted treatments

Focus on improving survival rates and quality of life for patients with various cancer types.

04 Cardiovascular Medicine

Innovative research in acute myocardial infarction management and prevention, with emphasis on emergency interventions.

Self-administered treatments
Emergency care protocols
Preventive strategies

Studies aim to improve rapid response and outcomes in cardiac emergencies.

Back to Italy All countries